About this item:

551 Views | 0 Downloads

Author Notes:

Address reprint requests and correspondence to Charles R. Harper, MD, Department of Medicine, Emory University, 49 Jesse Hill Junior Drive SE, Atlanta, GA 30303 (charper@emory.edu).

Dr Jacobson has been a consultant for AstraZeneca, GlaxoSmithKline, Merck, Schering-Plough, and Abbott Laboratories.


Using Apolipoprotein B to Manage Dyslipidemic Patients: Time for a Change?


Journal Title:

Mayo Clinic Proceedings


Volume 85, Number 5


, Pages 440-445

Type of Work:

Article | Post-print: After Peer Review


Low-density lipoprotein cholesterol (LDL-C) concentration has been established as an independent risk factor for the development of atherosclerosis; consequently, multiple practice guidelines recognize LDL-C as the primary target of therapy.1 and 2 For decades, considerable effort has been committed to educating physicians and the general public about the importance of lowering LDL-C levels.

Copyright information:

© 2010 Mayo Foundation for Medical Education and Research

Export to EndNote